Supernus Pharmaceuticals's total assets for Q3 2025 were $1.42B, an increase of 2.70% from the previous quarter. SUPN total liabilities were $370.09M for the fiscal quarter, a 16.20% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.